|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Canonical Janus kinase 2 (JAK2) V617F and exon 12 mutations in myeloid neoplasms are well described.
|
30811597 |
2019 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the current study, we found that suppressor of cytokine signaling proteins 3 (SOCS3) possessed the tumor suppressive activity against the JAK2 V617F mutant-provoked cellular transformation.
|
31255914 |
2019 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The expanding scope of creative impact is perhaps most startling-from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1β, PD-1, RANK-L) to cancer interception.
|
30530635 |
2018 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study suggests that autophagy as well as the anti-apoptotic BCL-2 family members, regulated at least partly by the mTORC1 pathway downstream of STAT5/Pim-2, protects JAK2-V617F-positive leukemic cells from ruxolitinib-induced apoptosis depending on cell types and may contribute to development of new strategies against JAK2-V617F-positive neoplasms.
|
29928488 |
2018 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We herein elucidated the mechanism by which CIS functions as a novel type of tumor suppressor in JAK2 V617F mutant-induced tumorigenesis.
|
28038963 |
2017 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data indicate that the same germ line variants endow individuals with a predisposition not only to MPN, but also to JAK2 V617F clonal hematopoiesis, a more common phenomenon that may foreshadow the development of an overt neoplasm.
|
27365426 |
2016 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
JAK2 V617F allele burden quantified by real time quantitative polymerase chain reaction and competitive polymerase chain reaction in patients with chronic myeloproliferative neoplasia.
|
23607255 |
2014 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Importantly, administration of DFMO effectively delayed tumor formation in nude mice inoculated with transformed cells by JAK2 (V617F), resulting in prolonged survival; therefore, ODC expression through c-Myc is a critical step for JAK2 (V617F)-induced transformation and DFMO could be used as effective therapy for MPNs.
|
23300995 |
2013 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, a point mutation in the JAK2 gene, JAK2 (V617F) , was discovered in several myeloid proliferative neoplasms including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
23666689 |
2013 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Measurement of allele burden on day 28 after transplantation discriminates two prognostic groups: patients with a JAK2 p.V617F allele burden >1% have a significantly higher risk of relapse of JAK2 p.V617F positive neoplasia (P=0.04) and a poorer overall survival (P<0.01).
|
23300178 |
2013 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, JAK2 V617F-mediated up-regulation of OSM may contribute to fibrosis, neoangiogenesis, and the cytokine storm observed in MPNs, suggesting that OSM might serve as a novel therapeutic target molecule in these neoplasms.
|
22051730 |
2012 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under question, and there has been interest in identifying additional mutations that may contribute to disease pathogenesis.
|
21712540 |
2011 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and kinase activation, has been incorporated into the WHO classification and diagnostic criteria of myeloid neoplasms.
|
22028900 |
2011 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81).
|
20538800 |
2010 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F.
|
20061559 |
2010 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutations in the TET2 gene have been identified in both JAK2 V617F-positive and -negative MPNs and other myeloid neoplasms, but their functional and clinical significance have yet to be clarified.
|
21082983 |
2010 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The frequency of JAK2 V617F mutation is about 90% in patients with PV, 50-60% in patients with essential thrombocythemia (ET), primary myelofibrosis (PMF), and less in patients with other myeloid neoplasms, while extremely rare in lymphoid malignancies.
|
19167611 |
2009 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed a retrospective analysis of JAK2 V617F mutation in Chinese patients with myeloid neoplasms and isolated del(5q), and were able to demonstrate the frequent occurrence of JAK2 V617F mutation in 5q- syndrome.
|
19562618 |
2009 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
|
18555525 |
2008 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data suggest that WP1066 is active both in vitro and ex vivo and should be further developed for the treatment of neoplasms expressing the JAK2 V617F mutation.
|
18245540 |
2008 |
|
rs77375493
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated whether low levels of JAK2(V617F) are present in lymphoid neoplasms using a highly sensitive and highly specific amplification refractory mutation system PCR (ARMS-PCR) assay.
|
18032883 |
2007 |